These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10585138)
21. Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene. Weijer K; Pfauth A; van Herwijnen R; Jarrett O; Meloen RH; Tomee C; Osterhaus AD Vaccine; 1993; 11(9):946-56. PubMed ID: 7692683 [TBL] [Abstract][Full Text] [Related]
22. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812 [TBL] [Abstract][Full Text] [Related]
23. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM Expert Rev Vaccines; 2011 Nov; 10(11):1569-83. PubMed ID: 22043956 [TBL] [Abstract][Full Text] [Related]
24. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. Zhu X; Tommasino M; Vousden K; Sadovnikava E; Rappuoli R; Crawford L; Kast M; Melief CJ; Beverley PC; Stauss HJ Scand J Immunol; 1995 Nov; 42(5):557-63. PubMed ID: 7481562 [TBL] [Abstract][Full Text] [Related]
25. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. van der Most RG; Sette A; Oseroff C; Alexander J; Murali-Krishna K; Lau LL; Southwood S; Sidney J; Chesnut RW; Matloubian M; Ahmed R J Immunol; 1996 Dec; 157(12):5543-54. PubMed ID: 8955205 [TBL] [Abstract][Full Text] [Related]
27. The quality of papers in Viral Immunology continues to rise. Woodland DL Viral Immunol; 2010 Apr; 23(2):125-6. PubMed ID: 20373992 [No Abstract] [Full Text] [Related]
28. Vaccination with Rev and Tat against AIDS. Osterhaus AD; van Baalen CA; Gruters RA; Schutten M; Siebelink CH; Hulskotte EG; Tijhaar EJ; Randall RE; van Amerongen G; Fleuchaus A; Erfle V; Sutter G Vaccine; 1999 Jun; 17(20-21):2713-4. PubMed ID: 10418922 [No Abstract] [Full Text] [Related]
29. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039 [TBL] [Abstract][Full Text] [Related]
30. A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. Francis MJ; Hastings GZ; Sangar DV; Clark RP; Syred A; Clarke BE; Rowlands DJ; Brown F J Gen Virol; 1987 Oct; 68 ( Pt 10)():2687-91. PubMed ID: 2822846 [TBL] [Abstract][Full Text] [Related]
31. Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection. Hu SL; Travis BM; Stallard V; Abrams K; Misher L; Moran P; Zarling JM; Langlois AJ; Kuller L; Morton WR AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1489-94. PubMed ID: 1466988 [No Abstract] [Full Text] [Related]
32. Full protection in mink against mink enteritis virus with new generation canine parvovirus vaccines based on synthetic peptide or recombinant protein. Langeveld JP; Kamstrup S; Uttenthal A; Strandbygaard B; Vela C; Dalsgaard K; Beekman NJ; Meloen RH; Casal JI Vaccine; 1995 Aug; 13(11):1033-7. PubMed ID: 8525686 [TBL] [Abstract][Full Text] [Related]
33. Synthetic peptides against foot-and-mouth disease--immunization with VP1-peptides of type O1-Kaufbeuren. Liebermann H; Holl U; Reimann I; Nöckler A; Schäfer D; Thalmann G; Dölling R Arch Exp Veterinarmed; 1990; 44(6):883-90. PubMed ID: 1966360 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. van Hall T; van der Burg SH Adv Immunol; 2012; 114():51-76. PubMed ID: 22449778 [TBL] [Abstract][Full Text] [Related]
35. Perspectives on FIV vaccine development. Elyar JS; Tellier MC; Soos JM; Yamamoto JK Vaccine; 1997; 15(12-13):1437-44. PubMed ID: 9302758 [TBL] [Abstract][Full Text] [Related]
37. Galactose oxidation as a potent vaccine adjuvant strategy. Efficacy in murine models and in protection against a bovine parasitic infection. Rhodes J; Zheng B; Morrison CA Ann N Y Acad Sci; 1995 May; 754():169-86. PubMed ID: 7625651 [TBL] [Abstract][Full Text] [Related]
38. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. Burrows SR; Gardner J; Khanna R; Steward T; Moss DJ; Rodda S; Suhrbier A J Gen Virol; 1994 Sep; 75 ( Pt 9)():2489-93. PubMed ID: 7521394 [TBL] [Abstract][Full Text] [Related]
39. Human cytotoxic T cell responses to vaccinia virus vaccination. Graham S; Green CP; Mason PD; Borysiewicz LK J Gen Virol; 1991 May; 72 ( Pt 5)():1183-6. PubMed ID: 2033393 [TBL] [Abstract][Full Text] [Related]